Safety of cangrelor and transition to oral P2Y(12) inhibitors in patients undergoing percutaneous coronary intervention: the ARCANGELO study

AIMS: Cangrelor is the only intravenous P2Y(12) inhibitor available. Safety, efficacy, and transitioning from cangrelor to oral P2Y(12) inhibitors were recorded in patients with acute coronary syndrome (ACS). The ARCANGELO study aims to assess the safety of cangrelor on bleeding and the effects of t...

Descripción completa

Detalles Bibliográficos
Autores principales: De Luca, Leonardo, Calabrò, Paolo, Capranzano, Piera, Di Mario, Carlo, Chirillo, Fabio, Rolfo, Cristina, Menozzi, Alberto, Menichelli, Maurizio, Bolognese, Leonardo, Musumeci, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462400/
https://www.ncbi.nlm.nih.gov/pubmed/37646045
http://dx.doi.org/10.1093/ehjopen/oead076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462400/
https://www.ncbi.nlm.nih.gov/pubmed/37646045
http://dx.doi.org/10.1093/ehjopen/oead076

Ejemplares similares